This biotech is working on a GLP-1 pill that could be better than the Wegovy version
The wave of GLP-1–based drugs has reshaped the treatment of obesity and type 2 diabetes, with Novo Nordisk’s weekly injection Wegovy setting the modern efficacy benchmark and igniting unprecedented demand. But the next battle isn’t just about more weight loss; it’s about how people take these medicines. A fast-rising biotech is now developing a once-daily GLP-1 pill designed to match or surpass Wegovy-level outcomes while removing the needle, refrigeration, and training that come with injections. If it delivers, the impact on patient adoption, access, and the broader market could be profound.
Why a pill could beat a shot, even at the same efficacy
– Convenience and adherence: Many patients simply prefer pills. A daily tablet can be easier to start, stick with, and titrate than a weekly injection, particularly for people with needle aversion or busy routines.
– Manufacturing and access: Oral small molecules can often be produced at large scale with simpler supply chains and without cold storage, potentially easing the shortages that have dogged injectables and, over time, helping bring costs down.
– Broader uptake: Primary care adoption is typically higher for oral therapies, and payers may prefer options that improve adherence and reduce administrative overhead—especially if outcomes match injections.
The biotech making a serious run at it
Among the new crop, Viking Therapeutics has drawn outsized attention with an oral program built on its dual-agonist technology (targeting GLP-1 and GIP). The company first established proof-of-concept with its injectable VK2735 and then advanced an oral formulation aimed at delivering comparable biology without needles.
Early clinical readouts from the oral version have shown meaningful weight reduction within the first month of dosing in healthy volunteers with elevated BMI, alongside a tolerability profile consistent with the class (nausea, vomiting, and diarrhea typically mild to moderate and dose-dependent). These short-duration results aren’t meant to compete head-to-head with Wegovy’s 68-week outcomes, but they are a crucial signal: the mechanism is active, the pill is absorbable, and the side effects appear manageable at doses that move weight.
What “better than Wegovy” would actually mean
– Equal or greater weight loss: Wegovy has demonstrated around 15% average weight loss at 68 weeks. To be considered better on efficacy alone, a pill would need to match or exceed that over a similar period, ideally with faster onset and robust maintenance.
– Tolerability at scale: GLP-1 pathways are notorious for gastrointestinal side effects. A winning pill would need low discontinuation rates and a side-effect profile that supports real-world adherence.
– Cardiometabolic breadth: Improvements in A1c, lipids, blood pressure, liver fat, and inflammatory markers will matter as obesity care moves toward holistic metabolic risk reduction.
– Practical advantages: Room-temperature stability, predictable pharmacokinetics, straightforward dose titration, and competitive cost of goods are not just niceties—they’re key to unlocking supply and access.
How the science of oral GLP-1s is evolving
There are two main approaches to turning GLP-1 biology into a pill:
1) Peptide pills with absorption enhancers. Novo Nordisk’s oral semaglutide (approved as Rybelsus for diabetes and being studied at higher doses for obesity) is a peptide co-formulated with an agent that helps it cross the gastric lining. Peptide pills can closely mimic injectable biology but require tight dosing instructions and often higher doses to overcome low bioavailability.
2) Non-peptide small molecules. Companies like Eli Lilly (orforglipron), Pfizer (once-daily danuglipron in development), Structure Therapeutics (next-generation GLP-1 agonists), and Roche’s Carmot acquisition (CT-996) are testing orally available small molecules that activate the GLP-1 receptor. These can be easier to manufacture and distribute at scale, but they must balance potency, selectivity, and safety to deliver durable weight loss without off-target effects.
Viking’s bet is slightly different: extend the benefits of dual agonism—where adding GIP signaling can deepen weight loss and may improve GI tolerability—into a convenient oral format. If successful, that combination could deliver Wegovy-class efficacy with a smoother patient experience.
The competitive bar keeps rising
– Injectables: Wegovy set the benchmark, but next-generation injectables from Eli Lilly (tirzepatide, already approved for obesity as Zepbound) have pushed average weight loss into the 20% range in some studies, resetting expectations for what “best-in-class” looks like.
– Oral contenders: Lilly’s oral small molecule orforglipron produced double-digit weight loss in phase 2 and is now in phase 3 for obesity and diabetes, making it the oral candidate to beat on timing and efficacy. Roche’s CT-996 and Pfizer’s once-daily danuglipron aim to follow, while Structure Therapeutics has pursued improved small molecules after earlier mid-stage testing.
What to watch next from the biotech
– Longer, placebo-controlled trials: Month-long signals are encouraging, but the critical test is 6–12+ months of data on weight reduction, metabolic endpoints, and discontinuation rates.
– Dose-ranging and titration: The best oral programs will pair efficacy with thoughtful titration schedules to minimize nausea and vomiting without blunting weight loss.
– Real-world readiness: Manufacturing capacity, room-temperature stability, and payer strategy will matter as much as the clinical profile if the goal is widespread adoption.
Regulatory timelines and market impact
Oral GLP-1s are on track to arrive in stages over the next several years. The first approvals among the current wave could come as early as the mid-to-late 2020s for programs already in phase 3. Biotechs like Viking, still earlier in oral development, could follow with differentiated profiles—especially if dual agonism in a pill proves to be a sweet spot on efficacy and tolerability.
If a biotech’s GLP-1 pill can consistently approach or exceed Wegovy’s weight loss while simplifying how people take the drug, it would represent more than incremental progress. It could shift prescribing from specialty to primary care, ease supply bottlenecks, and expand treatment to millions more people who want proven efficacy without injections. That, in practical terms, is how a pill could be “better than the Wegovy version”—even before we get into whether it can also beat it on the scale.
Bottom line
The obesity drug race is moving from “how much weight?” to “how will people actually take it long term?” A biotech advancing a well-tolerated GLP-1 pill with Wegovy-class efficacy could upend the current pecking order. The science is catching up to the ambition, and the next 12–24 months of oral data will tell us whether convenience and scale can finally meet the gold-standard outcomes patients and clinicians now expect.
